Abiopharma

🔍 Malik Astha (Executive)

Company: Braze, Inc. (BRZE)

Report Date: 2026-08-19

Detailed Transactions and Holdings:

• Sold 7,794 shares of Class A Common Stock at $28.74 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 334,163.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 7,530 shares of Class A Common Stock at $30.36 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 326,633.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 400 shares of Class A Common Stock at $30.75 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 326,233.00 | transaction_form_type: 4 | Footnotes: F1, F5, F3

Footnotes:

• F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2026.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.73 to $29.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: Of the reported shares, 281,307 shares are represented by restricted stock units and performance-based restricted stock units.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.73 to $30.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.73 to $30.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.